SC
ENTA icon

SummitTX Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

SummitTX Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76M Buy
+257,702
New +$3.46M 0.1% 231

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SummitTX Capital's ENTA Position: Q2 2026 in Review

SummitTX Capital opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 257,702 shares worth $3.76M. The stake represents 0.1% of the portfolio and ranks #231 among its holdings.

123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • SummitTX Capital held 257,702 shares of Enanta Pharmaceuticals worth $3.76M as of Q2 2026.
  • Enanta Pharmaceuticals was a new SummitTX Capital position in Q2 2026.
  • Enanta Pharmaceuticals made up 0.1% of SummitTX Capital's portfolio in Q2 2026, its #231 holding.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.